The Manufacturers Life Insurance Company Has $2.82 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

The Manufacturers Life Insurance Company lessened its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 15.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,643 shares of the company’s stock after selling 13,558 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.12% of Apogee Therapeutics worth $2,819,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. EntryPoint Capital LLC lifted its stake in shares of Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after acquiring an additional 617 shares during the period. Kennedy Capital Management LLC acquired a new position in shares of Apogee Therapeutics during the first quarter valued at $212,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Apogee Therapeutics during the second quarter valued at $143,000. Ameritas Investment Partners Inc. lifted its stake in shares of Apogee Therapeutics by 111.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after acquiring an additional 2,172 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in shares of Apogee Therapeutics during the first quarter valued at $339,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Apogee Therapeutics Trading Up 1.6 %

NASDAQ:APGE opened at $56.11 on Wednesday. Apogee Therapeutics, Inc. has a 1-year low of $14.19 and a 1-year high of $72.29. The business’s 50-day moving average price is $49.95 and its two-hundred day moving average price is $49.05. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -10.69 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60). Sell-side analysts predict that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total value of $374,972.90. Following the transaction, the insider now owns 274,128 shares of the company’s stock, valued at approximately $15,422,441.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90. Following the sale, the insider now owns 274,128 shares of the company’s stock, valued at $15,422,441.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the sale, the chief executive officer now directly owns 1,434,487 shares in the company, valued at approximately $58,268,861.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 146,665 shares of company stock valued at $7,058,635. 36.10% of the stock is currently owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.